NeoGenomics Inc (NEO)
NeoGenomics Inc. is a healthcare company listed on the NASDAQ that operates cancer-focused testing laboratories in the United States and the United Kingdom. Through its laboratory network, the company provides diagnostic and related testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories. Its service portfolio includes cytogenetics, fluorescence in-situ hybridization, flow cytometry, immunohistochemistry, digital imaging, molecular testing, and morphologic analysis. NeoGenomics also supports pharmaceutical clients with oncology testing services tied to discovery and commercialization programs. Founded in 2001 and headquartered in Fort Myers, Florida, the company focuses on laboratory-based testing used in cancer care and research.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-NEO
|
$12.14
|
-16.7% Downside
|
Fair
|
$16.22
|
11.3% Upside
|
Fair
|
Good
|
—
|
—
|
—
|
0.0%
|
July 28, 2026
|
-19.1x
|
2.3x
|
2.5x
|
1.854 B
|
2.157 B
|
18.1%
|
90.8%
|
2.6
|
—
|
5.1%
|
